Skip to main content
Joseph Hulihan, MD, Neurology, Newtown, PA

JosephHulihanMD

Neurology Newtown, PA

Neurophysiology

Principal at Paradigm Consulting, LLC

Dr. Hulihan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hulihan's full profile

Already have an account?

Education & Training

  • Drexel University College of Medicine/Hahnemann University Hospital
    Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 1987 - 1990
  • Drexel University College of Medicine/Hahnemann University Hospital
    Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 1986 - 1987
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 1986

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1988 - 2022
  • MN State Medical License
    MN State Medical License 1990 - 1991
  • American Board of Psychiatry and Neurology Neurology

Publications & Presentations

PubMed

Press Mentions

  • Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update
    Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline UpdateAugust 3rd, 2021
  • Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference
    Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect ConferenceJanuary 6th, 2021
  • Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)
    Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)July 30th, 2020